Biotie Therapies - Major shareholder announcements

Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act

BIOTIE THERAPIES CORP.             STOCK EXCHANGE RELEASE      16 June 2015 at
10.00 a.m.

Notification according to Chapter 9, Section 5 of the Finnish Securities Markets
Act

Biotie Therapies Corp. (the "Company" or "Biotie") has received a notification
in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act
from UCB S.A. ("UCB").

The notification refers to the underwriting agreement to which UCB is a party
and which has been entered into in relation to the U.S. public offering of
American Depositary Shares representing the Company's shares (the "U.S.
Offering"), as announced by the Company.

According to the notification, the consummation of the U.S. Offering in
accordance with the said underwriting agreement would lead to the number of
shares in the Company held by UCB being reduced by 41,566,640 shares. As a
consequence, UCB would then be holding 70 shares, which is less than 5 per cent
of all the shares and votes in the Company.

On the date of this release, the number of shares in Biotie amounts to
455,968,174, of which 2,605,691 shares are held by the Company and its
subsidiaries.



In Turku, June 16, 2015

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

David Cook, CFO
Tel. +358 2 2748 900, e-mail: david.cook@biotie.com

DISTRIBUTION:

NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com






[HUG#1928722]